Industrivarden AB Class A (IDVA) Stock Forecast & Price Target
IDVA Analyst Ratings
There are no analyst ratings in the last 3 months.
IDVA Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Emil Nystedt | Kepler Capital | EUR 43.63 | sell | -8.11%Downside | Reiterated | 04/23/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Emil Nystedt | 04/23/26 | EUR 43.63 | sell | -8.11%Downside | Reiterated | Kepler Capital |
Best Analysts Covering Industrivarden AB Class A
Copying Emil Nystedt's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -7.10% per trade.
Copying Emil Nystedt's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.20% per trade.
Copying Emil Nystedt's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -2.20% per trade.
IDVA Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 0 | 0 | 0 | 0 |
In the current month, IDVA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IDVA average Analyst price target in the past 3 months is ―.
IDVA Financial Forecast
IDVA Earnings Forecast
Next quarter’s earnings estimate for IDVA is -EUR 0.34 with a range of ― to ―. The previous quarter’s EPS was -EUR 0.34. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
IDVA Sales Forecast
Next quarter’s sales forecast for IDVA is EUR 11.71M with a range of ― to ―. The previous quarter’s sales results were EUR 11.71M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
